ACS Chemical NeuroscienceOctober 13, 2025Rajiv Agrawal, Daniel J. Gillie, Alison E. Mungenast et al.8 citations
Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical neurons has been hypothesized to explain the rapid and enduring therapeutic effects of psychedelics and the dissociative anesthetic ketamine. However, safety concerns related to hallucinogenic/dissociative properties have limited the addressable...
A depressão é um transtorno de grande impacto clínico e social, frequentemente resistente ao tratamento convencional, o que motiva a busca por estratégias terapêuticas complementares. Psicodélicos como a psilocibina e o MDMA têm se destacado por induzir respostas rápidas e duradouras em sintomas depressivos. Esta revisão integrativa analisou 14 estudos publicados entre 2015 e 2024, selecionados...
Psychedelic-assisted therapies are re-emerging as credible options in psychological care amid a high global burden of mental ill-health and limited response to first-line treatments. Once marginal, psychedelics are now part of mainstream research and policy debate, while remaining illegal or tightly restricted in many jurisdictions. Classic and atypical compounds (e.g., psilocybin, MDMA) act...
Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to enhance and personalize neural...
Revista fisio&terapiaOctober 8, 2025Maurício Pedro Luciano da Costa, Pedro Bruschi Peiretti, Pedro Vinicius Rodrigues Silveira Silva et al.
A resurgence of scientific and clinical interest in psychedelic-assisted therapies, particularly with Psilocybin, has been observed. This paper presents an integrative literature review aiming to identify the scientific contributions, potential benefits, and limitations of the therapeutic use of psilocybin in mental health. The study followed a rigorous protocol. Searches were conducted in the...
MycologiaOctober 7, 2025Scott Ostuni, Pietro Voto, Joshua Birkebak et al.
Panaeolus oligotrophus sp. nov., a species macromorphologically resembling Panaeolus cinctulus, was collected in central Florida. Its macro- and micromorphological features are described and compared with all other known Panaeolus species. Color photos of the fruiting bodies and micrographs of key microscopic features are provided, along with an updated phylogenetic analysis. A microscopic...
Psilocybin, and its active metabolite psilocin, have seen renewed interest due to studies suggesting potential therapeutic utility. 5-Hydroxytryptamine2A receptors (5-HT 2A Rs) are primary mediators of the psychoactive effects of psychedelics in animals and humans, but the underlying neurobiological mechanisms remain poorly understood. Functional magnetic resonance imaging identified...
Eine Gruppe von Patienten, die schlecht auf Psychotherapie und Medikamente ansprechen, sind Patienten mit der Diagnose einer behandlungsresistenten Depression (TRD). Ein relativ neuer und erfolgreicher Psychotherapieansatz, der auch an der Psychiatrischen Klinik Münsterlingen unter der Leitung von Dr. Krähenmann (Ärztlicher Direktor der Psychiatrischen Dienste Thurgau) umgesetzt wird, ist das...
Abstract Psychedelic-assisted therapies are emerging as novel treatments of interest for a range of mental health issues, including eating disorders such as anorexia nervosa. Psychedelics, such as LSD and psilocybin, may exert biological and psychological effects pertinent to the pathophysiology of eating disorders. Initial clinical trials are underway to confirm the safety and therapeutic...
Die psychedelika assistierte Psychotherapie erfährt aktuell eine wissenschaftlich fundierte Renaissance. Studien zeigen eine therapeutische Wirksamkeit von Substanzen wie Psilocybin, LSD und MDMA bei verschiedenen psychischen Störungsbildern, insbesondere bei therapieresistenter Depression, PTBS, Angstund Suchterkrankungen. In der Schweiz nimmt diese Entwicklung eine besondere Stellung ein: Als...